Profitable aesthetics
Which area of the pharmaceutical market is the most attractive…
FDA extends review on Dynavax's Heplisav-B
The fate of the vaccine against hepatitis B, Heplisav-B, from…
Single Market of EAEU - opportunities for pharma
Common regulatory setting and common market for medicines have…
Tecentriq needs revision
Roche and NICE cannot agree again, this time about the Tecentriq…
FDA approved Idhifa
Thanks to the FDA’s accelerated approval Tuesday of Idhifa…
Vaccines boost sales
For three of the world’s top four vaccine companies, sales…